Therapeutic results of diffuse large B- Cell lymphoma N.Ait Amer; F.Tensaout; H.Moussaoui; F.Belhadri; N.Abdennebi; F.Boukhamia; D.Benali; L.Metidji; S.Zeghouati;
Asymptomatic Aortic Regurgitation Elie Chammas, MD.FESC Clemenceau Medical Center & Lebanese University.
Conventional
Conventional Antipsychotics 2 19 2007
Comparison of a portal image with reference images (simulation films or digitally reconstructed radiographs – DRRs)
1 orlowski targeted-therapies
Patricia S. Steeg, Ph.D. Director, Molecular Therapeutics Program Chief, Women’s Cancers Section, Laboratory of Pathology National Cancer Institute Bethesda,
Ponatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant or.
A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts)
Suvremena Terapija Atrijalne Fibrilacije Kantonalna Bolnica Zenica Enes Abdović.
Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.
Cardiostim 2012 Termination of Atrial Fibrillation by Catheter Ablation Can Be Successfully Predicted from Baseline ECG Buttu A. 1, Van Zaen J. 1, Viso.
